Childhood Cancer Data Initiative Annual Symposium (Abstract Registration): Submission #47

serial: '47'
sid: '150060'
uuid: eb3be377-e947-4a52-af58-05e13916be10
uri: /nci/ccdisymposium/abstract
created: '1756351533'
completed: '1756352560'
changed: '1756352560'
in_draft: '0'
current_page: ''
remote_addr: 10.208.28.150
uid: '0'
langcode: en
webform_id: ccdi_symposium_abstract
entity_type: node
entity_id: '2139'
locked: '0'
sticky: '0'
notes: ''
metatag: meta
data:
  authors_:
    - add_author_degree: B.S.
      add_author_first_name: Lucas
      add_author_last_name: Ebert
      add_author_middle: ''
      add_author_organization: 'Michigan Medicine'
    - add_author_degree: MPH
      add_author_first_name: 'Malay '
      add_author_last_name: Mody
      add_author_middle: ''
      add_author_organization: 'Michigan Medicine'
    - add_author_degree: M.D.
      add_author_first_name: Joshua
      add_author_last_name: Goldman
      add_author_middle: ''
      add_author_organization: 'Michigan Medicine'
    - add_author_degree: 'M.D., M.S. '
      add_author_first_name: David
      add_author_last_name: Hanauer
      add_author_middle: ''
      add_author_organization: 'Michigan Medicine'
    - add_author_degree: M.S.
      add_author_first_name: Jamie
      add_author_last_name: Estill
      add_author_middle: ''
      add_author_organization: 'Michigan Medicine'
    - add_author_degree: Ph.D.
      add_author_first_name: Brian
      add_author_last_name: Magnuson
      add_author_middle: ''
      add_author_organization: 'Michigan Medicine'
    - add_author_degree: M.D.
      add_author_first_name: Carl
      add_author_last_name: Koschmann
      add_author_middle: ''
      add_author_organization: 'Michigan Medicine'
    - add_author_degree: 'M.D., Ph.D.'
      add_author_first_name: Arul
      add_author_last_name: 'Chinnaiyan '
      add_author_middle: ''
      add_author_organization: 'Michigan Medicine'
    - add_author_degree: 'M.D., M.S. '
      add_author_first_name: Rajen
      add_author_last_name: Mody
      add_author_middle: ''
      add_author_organization: 'Michigan Medicine'
    - add_author_degree: Ph.D.
      add_author_first_name: 'Chandan '
      add_author_last_name: Kumar
      add_author_middle: ''
      add_author_organization: 'Michigan Medicine'
  abstract: |
    Our primary aim is to study the real-world impact of integrative clinical sequencing (ICS) based pediatric precision oncology program on the outcomes of pediatric-AYA cancer patients at a single institution. 
    Methods: Pediatric-AYA oncology patients (age 0-25yr) were enrolled and sequenced using methodology described previously.1 Longitudinal clinical data extracted from EHR using NCI supported tool EMERSE were entered into a REDCap. 
    Results: Clinical characteristics are shown in Fig-1. Of 1000 patients enrolled, 925 (92.5%) were sequenced successfully, 235 (23.5%) underwent repeat ICS (Range 1-4). Interim analysis of the first 250 patients revealed 230 patients with full sequencing results. Of those, 133 (57.8%) patients had total 228 actionable alterations (AA) (mean1.71 AA /pt), of which 30 (13%) patients had germline AA.  Of the total AA, 64 patients had 84 SNV (Single Nucleotide Variants), 33 patients had 38 actionable fusions, and 46 had 76 actionable CNA’s (Copy Number Alterations). Fifty-one (22.2%) patients received a total of 96 targeted therapies (TT) supported by variant level evidence (VLE)2, 3 (L1=39, L2=5, L3=4, L4=4, Other=44), while 16 (7.0%) patients received 26 TT without AA based on clinician preference. Eighty-two (35.6%) patients with AA did not receive any TT. Sixty-five (28.3%) patients underwent repeat ICS, among which 9.2% (6) had additional AA identified and 4.6% (3) received TT based on repeat ICS.  
    Conclusion: Interim analyses showed that 67 patients (29.1%) received TT with variable level of evidence. Outcomes of patients receiving TT including, EFS, OS and barrier in receiving TT despite having AA, are under further analyses. 
  abstract_title_: 'Real-World Experience of Pediatric Precision Oncology Cohort At a Single Institution: An Interim Analysis'
  email_address_: rmody@med.umich.edu
  institution_: 'Michigan Medicine'
  presenting_author_: 'Lucas Ebert/ Malay Mody'